GammaCore™ Now Available Through U.S. Federal Government’s Federal Supply Schedule

Five-year contract makes gammaCore™ available to the over 21 million patients managed within the Department of Veteran’s Affairs, Department of Defense, Bureau of Prisons, Indian Health Services and Public Health Services

BASKING RIDGE, N.J., Jan. 02, 2019 — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced its non-invasive vagus nerve stimulation (nVNS) therapy, gammaCore™, has been awarded a five-year Federal Supply Schedule Medical Equipment and Supply contract which will make gammaCore available in January to the over 21 million patients managed within the Department of Veteran’s Affairs, Department of Defense, Bureau of Prisons, Indian Health Services and Public Health Services. 

“electroCore continues to focus on making gammaCore™ affordable, accessible and broadly available. With the FSS contract, we will deepen our commitment to the underserved patient population diagnosed with migraine or cluster headache, and are one step closer to ensuring patients who may benefit from gammaCore have access to this safe and effective therapy,” said Frank Amato, Chief Executive Officer, electroCore.

About gammaCore

gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy FDA-cleared as an adjunctive therapy for the preventative treatment of cluster headache and as an acute treatment for pain associated with episodic cluster headache and migraine headache in adult patients. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers leading to a modulation of neurotransmitters and a reduction in pain.

gammaCore™ is the only therapy FDA cleared for the prevention of cluster headache.

gammaCore™ is available by prescription only and patients should speak with their doctor about whether gammaCore is right for them.

gammaCore™ (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore™ is indicated for:

  • Adjunctive use for the preventive treatment of cluster headache in adult patients.
  • The acute treatment of pain associated with episodic cluster headache in adult patients.
  • The acute treatment of pain associated with migraine headache in adult patients.
  • The safety and effectiveness of gammaCore™ (nVNS) have not been established in the acute treatment of chronic cluster headache
  • gammaCore™ has not been shown to be effective for the preventive treatment of migraine headache
  • The long-term effects of the chronic use of gammaCore™ have not been evaluated
  • Safety and efficacy of gammaCore™ have not been evaluated in the following patients, and therefore it is NOT indicated for:
    • Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
    • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
    • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
    • Pediatric patients
    • Pregnant women
    • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
  • Patients should not use gammaCore™ if they:
  • Have a metallic device such as a stent, bone plate, or bone screw implanted at or near their neck
  • Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

NOTE: This list is not all inclusive. Please refer to the gammaCore™ Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

About Cluster Headache

Cluster headache is a series of relatively short but extremely painful headaches that has been described by patients and physicians as one of the most painful conditions in medicine. The suicide rate among these patients is 20 times the U.S. national average, leading to the condition being referred to as the “suicide headache.” There are approximately 350,000 cluster headache sufferers in the United States, approximately 225,000 of whom seek treatment each year primarily from the same headache specialists who treat migraine.

About Migraine

Migraine is a term used to describe a class of recurrent, pulsing headaches that are typically unilateral (on one side of the head) but may occur bilaterally (on both sides of the head) and may cause visual disturbances, nausea and vomiting. They may occur with or without recognized warning signs, including either prodromal symptoms or an aura phase. Prodromal symptoms consist of altered mood, irritability, depression or euphoria, fatigue, dizziness and other visceral symptoms preceding the headache by several hours or days. Auras can include visual disturbances such as photopsia or scotomas or, in less frequent cases, somatosensory, auditory or gustatory hallucinations.

There are approximately 39 million Americans living with migraine, and more than 100,000 migraines occur every day in the U.S. Migraine prevalence is significantly higher in females than in males, at a ratio of 3:1.

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

Forward-Looking Statement

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and product development plans, its pipeline or potential markets for its technologies, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.  Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.